Get the Stockscreener App
0.00
100.00%
-12.58
After Hours:
12.53
12.53
+
Astria Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$12.58
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$718.13M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
0.00
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$13.29
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
0.00 | 718.13M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
View All
Astria Therapeutics Inc Stock (ATXS) Latest News
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Bitget
BioCryst (BCRX) Achieves Record Revenue and Profitability Milest - GuruFocus
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Rare-disease drugmaker BioCryst turns first annual profit, wins FDA OK for kids - Stock Titan
BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed? - Yahoo Finance
ATXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Spikes: Can Astria Therapeutics Inc ride the EV waveQuarterly Earnings Report & Community Verified Trade Signals - baoquankhu1.vn
Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition - Insider Monkey
What are the future prospects of Astria Therapeutics Inc.2025 EndofYear Setup & Weekly High Potential Stock Alerts - mfd.ru
Can Astria Therapeutics Inc. ride the EV wave2025 Earnings Surprises & Technical Analysis for Trade Confirmation - mfd.ru
Is Astria Therapeutics Inc.’s ROE strong enoughTrade Volume Summary & Weekly Sector Rotation Insights - mfd.ru
BioCryst (BCRX) Poised for Growth with Key Acquisition and Positive Outlook - GuruFocus
Can Astria Therapeutics Inc. maintain its current growth rateJuly 2025 Trends & Capital Efficiency Focused Strategies - mfd.ru
Analyst Calls: Should I invest in Astria Therapeutics Inc before earnings2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap - Yahoo Finance
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy - MSN
Biocryst expands HAE treatment portfolio with Astria acquisition - Angioedema News
Can Astria Therapeutics Inc. stock beat market expectations this quarterMarket Movement Recap & Safe Capital Growth Plans - mfd.ru
Buyout Rumor: Can Astria Therapeutics Inc ride the EV waveEntry Point & Precise Trade Entry Recommendations - baoquankhu1.vn
Published on: 2026-01-28 20:41:53 - baoquankhu1.vn
Does Blackstone’s US$400 Million Deal and Astria Hires Change The Bull Case For BioCryst (BCRX)? - Sahm
Bearish Setup: Can Astria Therapeutics Inc. reach all time highs this yearMarket Sentiment Report & Fast Gaining Stock Reports - mfd.ru
Breakouts Watch: What dividend growth rate does Astria Therapeutics Inc offer2025 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn
Liquidity Mapping Around (ATXS) Price Events - Stock Traders Daily
Option Delisting: Astria Therapeutics (ATXS) to be Delisted - GuruFocus
BioCryst Completes Acquisition of Astria Therapeutics - Longbridge
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema - Sahm
Astria Therapeutics Completes Merger and Goes Private - TipRanks
Astria Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
BioCryst Completes Acquisition of Astria Therapeutics (ATXS) - GuruFocus
BioCryst completes $700 million acquisition of Astria Therapeutics - Investing.com
BioCryst completes $700 million acquisition of Astria Therapeutics By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics to Enhance HAE Portfolio - Quiver Quantitative
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
BioCryst: A Changed And Interesting Thesis For 2026 (NASDAQ:BCRX) - Seeking Alpha
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Hedge Fund Bets: Is Astria Therapeutics Inc trading at a discount2025 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Increases By 37.9% - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Why (ATXS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - MarketBeat
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® - GlobeNewswire
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - Yahoo Finance
Why Astria Therapeutics Inc. stock could outperform in 20252025 Major Catalysts & Free Long-Term Investment Growth Plans - ulpravda.ru
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - sharewise.com
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - PR Newswire
Growth Recap: Is Astria Therapeutics Inc stock in correction or buying zone2025 Trade Ideas & Consistent Profit Focused Trading Strategies - Bộ Nội Vụ
Understanding Momentum Shifts in (ATXS) - Stock Traders Daily
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):